Cargando…
Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer
Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies is downregulation or mutational loss of the nominal epitope. Targeting multiple antig...
Autores principales: | Shu, Runzhe, Evtimov, Vera J., Hammett, Maree V., Nguyen, Nhu-Y N., Zhuang, Junli, Hudson, Peter J., Howard, Maureen C., Pupovac, Aleta, Trounson, Alan O., Boyd, Richard L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868933/ https://www.ncbi.nlm.nih.gov/pubmed/33614914 http://dx.doi.org/10.1016/j.omto.2021.01.002 |
Ejemplares similares
-
Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy
por: Shu, Runzhe, et al.
Publicado: (2023) -
Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy
por: Islam, Rasa, et al.
Publicado: (2021) -
CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies
por: To, Van, et al.
Publicado: (2022) -
‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8(+) T Cells Derived from Hematopoietic Stem Cells
por: Boyd, Nicholas, et al.
Publicado: (2021) -
Effective Targeting of TAG72(+) Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells
por: Murad, John P., et al.
Publicado: (2018)